A five-year clinical study has revealed that spectacle lenses equipped with highly aspherical lenslets (HAL) can ...

Sydnexis, Inc. ( a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a ...

Spectacle lenses dominate Japan's myopia control market through cultural trust and accessibility, while multifocal and soft contact lenses gain tract ...

Andy Ingram, who has now had 19 separate operations, says his condition leaves him trying to hold his eyes straight for every ...

The EMA’s Committee for Medicinal Products for Human Use said that a phase 3 study in children aged 3-14 years demonstrated ...

Young adults with myopia who attend school may benefit from lower concentration atropine, which minimizes visual performance disruptions.

SYD-101 contains a low dose of atropine sulfate, an antimuscarinic agent, in an ophthalmic solution. The NDA is supported by data from the phase 3 STAR trial (ClinicalTrials.gov Identifier: ...

SYD-101 contains a low dose of atropine sulfate, an antimuscarinic agent, in an ophthalmic solution. The NDA is supported by data from the phase 3 STAR trial (ClinicalTrials.gov Identifier ...

safe and effective eye drop to pediatric myopia patients, their families, and clinicians.” The STAR study, a phase 3 clinical trial evaluating SYD-101’s proprietary low-dose atropine formulation to ...